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Abstract
Carnitine is a conditionally essential nutrient that plays a vital role in energy production and fatty acid metabolism. 
Vegetarians possess a greater bioavailability than meat eaters. Distinct deficiencies arise either from genetic mutation 
of carnitine transporters or in association with other disorders such as liver or kidney disease. Carnitine deficiency 
occurs in aberrations of carnitine regulation in disorders such as diabetes, sepsis, cardiomyopathy, malnutrition, 
cirrhosis, endocrine disorders and with aging. Nutritional supplementation of L-carnitine, the biologically active form of 
carnitine, is ameliorative for uremic patients, and can improve nerve conduction, neuropathic pain and immune 
function in diabetes patients while it is life-saving for patients suffering primary carnitine deficiency. Clinical application 
of carnitine holds much promise in a range of neural disorders such as Alzheimer's disease, hepatic encephalopathy 
and other painful neuropathies. Topical application in dry eye offers osmoprotection and modulates immune and 
inflammatory responses. Carnitine has been recognized as a nutritional supplement in cardiovascular disease and 
there is increasing evidence that carnitine supplementation may be beneficial in treating obesity, improving glucose 
intolerance and total energy expenditure.
Introduction
Carnitine (β-hydroxy-γ-N-trimethylaminobutyric acid) is
widely distributed in food from animals sources but there
is limited availability in plants [1]. In humans, 75% of car-
nitine is obtained from the diet [2]. L-carnitine (the bio-
logically active stereoisomer) is absorbed from foods via
both active and passive transport across enterocyte
(intestinal cell) membranes [3]. The bioavailability of L-
carnitine varies due to dietary composition. Bioavailabil-
ity of L-carnitine in individuals such as vegetarians who
are adapted to low-carnitine diets is higher (66% to 86%
of available carnitine) than regular red-meat eaters
adapted to high-carnitine diets (54% to 72% of available
carnitine) [4]. Carnitine not obtained from food is syn-
thesized endogenously from two essential amino acids,
lysine and methionine. This occurs in kidney, liver and
brain [5]. Cardiac and skeletal muscle, harboring the
highest concentrations, cannot synthesize carnitine and
so must acquire carnitine from plasma. Unabsorbed L-
carnitine is mostly degraded by microorganisms in the
large intestine [3]. Almost all carnitine (99%) is intracellu-
lar [5]. Carnitine influences carbohydrate metabolism.
Aberrations in carnitine regulation are implicated in
complications of diabetes mellitus, hemodialysis, trauma,
malnutrition, cardiomyopathy, obesity, fasting, drug
interactions, endocrine imbalances and other disorders.
The purpose of this review is to summarize the role of
carnitine in human nutrition and disease and highlight
the major areas of research in this field.
Carnitine biosynthesis and metabolism
Carnitine, a branched non-essential amino acid, is syn-
thesized from the essential amino acids lysine and methi-
onine. Ascorbic acid, ferrous iron, pyroxidine and niacin
are also necessary cofactors [1] and deficiencies of any of
these can lead to carnitine deficiency. The pathway in
mammals is unique using protein-bound lysine that is
enzymatically methylated to form trimethyllysine as a
post-translational modification of protein synthesis [6].
Trimethyllysine undergoes four enzymatic reactions in
the course of endogenous L-carnitine biosynthesis (Figure
1).
One of the enzymes in this pathway, γ-butyrobetaine
hydroxylase, is absent from cardiac and skeletal muscle
but highly expressed in human liver, testes, and kidney
[4]. The rate of L-carnitine biosynthesis in vegetarians is
estimated to be around 1.2 μmol/kg of body weight/day
[7]. Omnivorous humans ingest 2-12 μmol/kg of body
weight/day which represents 75% of body carnitine
sources [8]. Neither renal reabsorption nor changes in
dietary carnitine intake appear to affect the rate of endog-
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enous carnitine synthesis [9]. Bioavailability of oral carni-
tine dietary supplements is only in the order of 14 to 18%
of dose and unabsorbed L-carnitine is mostly degraded
by micoorganisims in the large intestine [3].
Free L-carnitine, absorbed from dietary intake or syn-
thesized in liver and kidney, reaches the blood stream and
the extracellular fluid. Its transport within cells of various
tissues is limited by their respective uptake capacities
[10]. Plasma concentration of free carnitine is in dynamic
balance with acylcarnitines with the acyl to fee carnitine
ration of ≤ 0.4 being considered normal [11]. Acetylcarni-
tine esters are formed intracellularly during regular meta-
bolic activity. Long chain acetylcarnitine esters transport
fatty acyl moieties into the mitochondria (Figure 2). Short
and medium-chain acetyl esters, formed in the mitochon-
dria and peroxisomes, participate in the removal of
organic acids [12]. Acetyl-L-carnitine is the principal
acylcarnitine ester [12]. Acetyl-L-carnitine participates in
both anabolic and catabolic pathways in cellular metabo-
lism [12].
Carnitine plays a critical role in energy balance across
cell membranes and in energy metabolism of tissues that
derive much of their energy from fatty acid oxidation
such as cardiac and skeletal muscles [13,14] (Figure 2).
Although carnitine plays its main role in carnitine free
fatty acid metabolism, it also enhances carbohydrate utili-
zation [15]. Uptake in skeletal and cardiac muscle is a sat-
urable active transport process against a concentration
gradient [16].
Figure 1 Carnitine biosynthesis and metabolism.
Figure 2 Carnitine is actively transported via OCTN2 into the cy-
tosol to participate in the shuttling of activated long chain fatty 
acids into the mitochondria where β-oxidation takes place. Carni-
tine also regulates the Coenzyme A (CoA)/acylCoA ratio within the mi-
tochondria, modulation of which reduces accumulation of toxic acyl-
CoA compounds and maintains energy production.
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Experimental evidence suggests that the transport of
long chain fatty acids into the mitochondria is a rate lim-
iting step in fatty acid oxidation. During sustained low to
moderate exercise, fatty acid oxidation increases to
become the predominant energy source to muscles [17].
CPTI (Figure 2) is a control point of FA oxidation and
decreased carnitine levels and acidosis of CPT1 have
been implicated in decreased fatty acid oxidation during
heavy exercise [18]. Deficiencies in CPTII may result in
exercise induced muscle injury due to inability to increase
FA oxidation with increased exertion.
Carnitine participates in cell volume and fluid balanc-
ing in all tissues that are affected by the tonicity (iso-,
hyper- hypo- tonicity) of the extracellular environment
[19]. Data suggest that despite fluctuations in carnitine
concentration due to its osmolytic pressure changes, car-
nitine maintains its energy production capacities and
often osmolytic gradients can be harnessed for
energy[19]. Carnitine fluctuates with both physiological
and pathological changes in osmotic pressure. In one
example of a physiological response to osmotic pressure,
in early mammary gland milk production osmoregulatory
pathways are exploited using asymmetric kinetics to
increase the carnitine concentration in milk for suckling
neonates who have reduced carnitine stores, even though
this results in decreased maternal liver stores [20].
Primary Carnitine Deficiency Syndromes
Two distinct carnitine deficiency states have been
reported although a rigid distinction between "primary"
and "secondary" carnitine deficiency is difficult to estab-
lish in some cases [10]. Primary carnitine deficiency
(PCD) is a rare autosomal recessive disorder of fatty acid
oxidation caused by deficiency of plasma membrane car-
nitine transport resulting from impairment in the plasma
membrane OCTN2 carnitine transporter. This deficiency
restricts tissue uptake, leading to decreased accumulation
in the heart and skeletal muscle and potentiates increased
renal carnitine loss [21,22] leading to systemic carnitine
depletion [23]. Due to defective renal absorption (free)
carnitine is excreted in the urine of patients with primary
deficiency and can result in tissue carnitine levels drop-
ping to below 10% of normal [14,22,24-26]. Genetic defi-
ciencies of transporter activity represent the only known
forms of primary carnitine deficiency [27].
PCD occurs in 1-5 per 10, 000 population and most
commonly manifests between ages 1-7 [28,29]. The most
common presentation of PCD is hypoketotic hypoglyce-
mic encephalopathy. Cardiomyopathy has also be
observed [30]. The gene responsible for PCD is SLC22A5.
Several mutations have been described
[21,22,25,26,29,31-33]. Three tissues/organs are affected
in PCD: cardiac muscle which leads to progressive cardi-
omyopathy; central nervous system which is affected by
encephalopathy caused by hypoketotic hypoglycaemia,
and skeletal muscle which is affected by myopathy [30].
For these patients, L-carnitine supplementation is a life-
saving treatment.
Three distinct clinical entities have been described; the
adult, the infantile, and the perinatal, all with an auto-
somal recessive inheritance pattern [34]. The different
mutations in SLC22A5 probably give rise to differences in
severity/onset of the disease. Measurement of free carni-
tine and total carnitine in plasma are important in the
diagnosis.
Carnitine transporter mutations in Crohn's disease
consists of missense mutation(s) in the gene coding
plasma membrane transporter OCTN1 (SLC22A4) and/
or mutation(s) in the promoter of the gene encoding
OCTN2 (SLC22A5) [14,35]. Manifestation of these muta-
tions results in disruption of a heat shock binding ele-
ment decreasing the transport function (OCTN1), and
reduced expression (through OCTN2 mutation) which
both result in carnitine deficiency [14]. These mutations
are in strong linkage disequilibrium, creating a two-allele
risk haplotype and hence increasing the overall risk of
this disease [14].
Secondary Carnitine deficiency
Secondary deficiency is characterized by increased carni-
tine excretion in urine in the form of acyl-carnitine due to
an accumulation of organic acids [36,37]. Secondary car-
nitine deficiency can be caused by increased losses, phar-
macological therapy, a number of inherited metabolic
disorders [38], poor diet or malabsorption of carnitine,
from increased renal tubular loss of free carnitine (Fan-
coni syndrome), haemodialysis, peritoneal dialysis, or the
increased excretion of acylcarnitines[39] with certain
drugs. There have been reported at least 15 syndromes in
which carnitine deficiency seems to be secondary to
genetic defects of intermediary metabolism or to other
conditions [40]. Patients with secondary carnitine defi-
ciency accumulate organic acids which causes enhanced
urinary excretion of carnitine in the form of acyl-carniti-
nes [36,37].
Secondary carnitine deficiency (SCD) is less severe
with respect to its short-term clinical impact and is much
more common [23]. As opposed to PCD, SCD occurs due
to, or in association with, other disorders such as liver or
kidney disease, defects in fatty acid metabolism, or
administration of pharmacological agents such as pivam-
picillin or valproic acid (discussed below) [27,41,42]. SCD
is seen in patients with renal tubular disorders, in which
there may be excessive excretion of carnitine, and in
hemodialysis patients. A lack of carnitine in dialysis
patients is caused by insufficient carnitine synthesis and
by the loss through dialytic membranes, leading, in some
patients, to carnitine depletion and a concomitant rela-Flanagan et al. Nutrition & Metabolism 2010, 7:30
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tive increase in esterified forms of carnitine [43]. L-Car-
nitine supplementation an lead to improvements in
several complications seen in uremic patients, including
cardiac complications, impaired exercise and functional
capacities, muscle symptoms, increased symptomatic int-
radialytic hypotension, and erythropoietin-resistant ane-
mia through normalizing the reduced carnitine palmitoyl
transferase activity in red cells [43]. Argani and col-
leagues showed a decrease in plasma levels of triglyceride
(TG) and very low-density lipoprotein, and increases in
total high-density lipoprotein cholesterol (HDL-C and
HDL2-C) and albumin, in hemodialysis patients upon
administration of 500 mg/day carnitine taken orally for 2
months [44].
Secondary genetic carnitine deficiency
CPT-1 deficiency
Carnitine palmitoyltransferase I (CPTI) deficiency is
thought to cause serious disorders of fatty acid metabo-
lism. The nucleotide sequences of cDNA and genomic
DNA encoding human CPTI have been characterized
[45,46]. However, a relationship between disease and
mutation of the human CPTI gene has not been reported
[47].
CPT II deficiency
The adult CPT II clinical phenotype is somewhat benign
a n d  r e q u i r e s  a d d i t i o n a l  e x t e r n a l  t r i g g e r s  s u c h  a s  h i g h -
intensity exercise before the predominantly myopathic
symptoms are elicited. The perinatal and infantile forms
involve multiple organ systems. The perinatal disease is
t h e  m o s t  s e v e r e  f o r m  a n d  i s  i n v a r i a b l y  f a t a l  [ 3 4 ] .  T h e
most frequent symptom of muscle palmitoyltransferase
CPT II deficiency is an exercise induced myalgia [1].
Myoglobinuria, the traditional hallmark of this disease
was not present in 21% patients in one study [48]. Myal-
gia typically starts in childhood while myoglobinuria
starts later in adolescence or early adulthood [1]. One
case study found a novel mutation in CPT II (del1737C),
an autosomal recessive disease with a distinct phenotype
[49]. A two- day old boy died due to severe hepatocardio-
muscular disease with an extreme early onset. His sister
also died. Upon autopsy the brother showed massive pul-
monary atelectasis with intra-alveolar hemorrhage, car-
dio- and hepato-megaly. The sister died of sudden
cardiopulmonary arrest due to the increase of long-chain
(C16-18) acylcarnitines. Decreased CPT II activity was
found in her liver, heart and kidney. The cause of death
was neonatal CPT II deficiency.
Acquired carnitine deficiency
Hemodialysis and kidney disorders
In the kidney, osmolytes including carnitine are crucial
since hypertonicity is usual and the kidney must cope
with fluctuations of diuresis (increased production of
urine) and antidiruesis. Extracellular osmolarity of med-
ullary cells may become more than four-fold that of isoto-
nicity [50]. In healthy individuals, carnitine is freely
filtered and tubular resorption of free carnitine (FC) is
almost complete. What is excreted in urine is carnitine
ester, or acylcarnitine (AC) [13]. In healthy people, the
renal clearance of AC is four to eight times that of FC [51-
53]. Impairment of excretion of AC occurs with deterio-
rating renal function leading to decreased carnitine clear-
ance and resulting in elevated plasma levels of carnitine
[ 1 3 ] .  U r e m i c  p a t i e n t s  h a v e  e l e v a t e d  l e v e l s  o f  A C  t h a t
occur as both elevated FC and total carnitine before dial-
ysis [52]. These patients experience accumulation of
plasma acylcarnitines, in part due to a decreased renal
clearance of esterified carnitine moieties [54]. Due to
accumulation of metabolic intermediates, impaired car-
nitine biosynthesis, reduced protein intake, and increased
removal of carnitine through hemodialysis (HD), patients
who undergo routine HD usually present with plasma
carnitine insufficiency [54]. During dialysis, patients
experience subnormal plasma/serum free carnitine con-
centrations [13] with plasma levels dropping by 60% with
a slow replacement from carnitine stores such as from
skeletal muscle during the interdialytic period.
Dietary intake also plays an important role in carnitine
homeostasis of HD patients since the prevalence of mal-
nutrition ranges from 18% to 75% of these cases [54].
Clinical consequences of such malnutrition can lead to
impaired muscle function, decreased wound healing,
altered ventilatory response, and abnormal immune func-
tion [54]. Repeated hemodialytic treatments can result in
depletion of skeletal muscle carnitine stores. Intravenous
L-carnitine (LC) following dialysis can replenish the free
carnitine removed from the blood and restore muscle
carnitine content, alleviating muscle myopathies and
impaired exercise capacity [13], as well as ameliorating
erythropoietin-resistant anemia, decreased cardiac per-
formance, intradialytic hypotension [54]. Furthermore,
LC may positively influence the nutritional status of HD
patients by promoting a positive protein balance, and by
reducing insulin resistance and chronic inflammation,
possibly through an effect on leptin resistance [54]. Han-
delman however cautions that evidence for effectiveness
of carnitine supplements in dialysis suffers from trials
limited in subject number and open labeled, and suggests
more rigorous testing is needed [55].
Cyclosporin A induced nephrotoxicity
Cyclosporine (CyA) is used as an immunosuppressive
agent following organ transplantation but its use is lim-
ited due to its associated nephrotoxicity. Bertelli et al.
[56] demonstrated that L-propionylcarnitine (L-PC), a
propionyl ester of L-carnitine, is able to prevent CyA-
induced acute nephrotoxicity, reducing lipid peroxidationFlanagan et al. Nutrition & Metabolism 2010, 7:30
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in the isolated and perfused rat kidney in vitro. In vivo
studies demonstrate that L-PC was able to significantly
lower blood pressure in CyA treated animals and to pre-
vent decrease creatinine clearance that normally results
from CyA administration [57]. Origlia and colleagues fur-
ther demonstrated L-PC-associated reduction in lipid
hydroperoxide content and morphological abnormalities
associated with chronic CyA administration [57].
Cirrhosis and liver disorders
Carnitine deficiency has been associated with cirrhosis
[5]. L-acyl-carnitine has been suggested as a potent, low-
cost, and safe alternative therapy for patients with cirrho-
sis [58]. Minimal hepatic encephalopathy (MHE) is a seri-
ous and common complication that occurs in the
majority of cirrhotic patients [59]. Malaguarnera and col-
leagues treating MHE patients with acetyl-L-carnitine
(ALC) exhibited recovery of neuropsychological activities
related to attention/concentration, visual scanning and
tracking, psychomotor speed and mental flexibility,
short-term memory, attention and computing ability, lan-
guage, orientation ability and cognitive activities [59].
There is a strong correlation between hepatic encephal-
opathy and abnormal ammonia handling, and ALC has
been shown to induce ureagenesis leading to decreased
blood and brain ammonia levels [60]. This is supported
by other studies that showed a protective effect of L-car-
nitine against ammonia-evoked encephalopathy in cir-
rhotic patients, with ALC administration improving
neurological symptoms and plasmatic parameters in cir-
rhotic patients with hepatic coma [60-67].
Carnitine depletion is common in patients hospitalized
for advanced cirrhosis and results from three factors;
substandard intake of dietary carnitine; substandard
intake of lysine and methionine; and loss of capacity to
synthesize carnitine from these two amino acids [68]. The
most likely reason for incapacity to synthesize carnitine
from lysine and methionine is inability to convert γ-buty-
robetaine to carnitine [68]. Chronic ingestion of alcohol
is known to cause hepatic steatosis [69,70]. Sachan et al.
[71] demonstrated that exogenous carnitine added to the
ethanol diet in an experimental rat model significantly
reduced lipid accumulation in livers which were other-
wise laden with lipids, suggesting that there is a defi-
ciency of functional carnitine i.e. carnitine which is
available for acylation [72]. Supplementation of the diet
with lysine can restore carnitine levels, however, there
appeared to be impairment of carnitine biosynthesis in
ethanol-compromised livers in the rat study [71]. It is
known that dietary absorption of amino acids is impaired
by ethanol so this could also contribute to carnitine defi-
ciency overall [73]. It appears that reduced plasma and
peripheral tissue carnitine levels result from sequestra-
tion by ethanol-compromised liver [71]. Sachan and col-
leagues conclude that dietary carnitine is effective in
preventing lipid accumulation that results from ethanol-
feeding of rats. Dietary carnitine proved to be an effective
hypolipidemic agent. Efficacy was related to degree of
hypercarnitinemia which is consistent with a deficiency
of functional carnitine biosynthesis in the ethanol fed rats
[71].
Obesity, endocrine disorders and diabetes
Evidence is mounting that carnitine supplementation
may be beneficial in obesity [5]. In obese rats manifesting
insulin resistance, carnitine supplementation improved
glucose tolerance and increased total energy expenditure
[5]. Carnitine palmitoyltransferase (CPT)-1 is the rate-
limiting step of the fatty acid oxidation pathway and a tar-
get for the treatment of obesity. Modulation of CPT-1
may affect energy metabolism and food intake, and
research is ongoing into the effects of both stimulation
and inhibition of CPT-1 and in relation to obesity man-
agement [74].
Pharmacological stimulation of brain carnitine palmi-
toyl-transferase-1 (CPT-1) was reported to decrease food
intake and body weight [75]. A selective CPT-1 stimula-
tor produced long lasting hypophagia (reduced food
intake) and persistent weight loss [75]. However, this is in
contrast with other studies that found CPT-1 inhibition
actually stimulated hypophagia [76,77] and weight loss
[77]. Thus further work needs to be done to clarify this
issue. There is some debate in the literature regarding
whether satiety depends on the cytosolic concentration of
long-chain fatty acids, with the suggestion that an
increased concentration correlates with satiety and
decreased feeding and body weight [77-80]. However, Aja
and colleagues found no evidence for this hypothesis
since in this model CPT-1 should inhibit feeding by
increasing cytosolic fatty-acyl CoA levels while they actu-
ally showed the initial response of mice to a CPT-1 inhib-
itor was an increase in appetite [75]. The authors discuss
whether CNS injection of the drug versus systemic treat-
ment may play an important role in the overall effect.
The development of type 2 diabetes is accompanied by
decreased immune function, the underlying mechanisms
of which are unclear. It has been suggested that oxidative
damage and mitochondrial dysfunction may play an
important role in the immune dysfunction in diabetes
[81]. This hypothesis was tested using mitochondrial tar-
geting nutrients in a diabetic rat model. Administration
of a combination of mitochondrial targeting nutrients,
including carnitine, suggested carnitine may be effective
in improving immune function in type 2 diabetes through
enhancement of mitochondrial function, decreased oxi-
dative damage, and delayed cell death in the immune
organs and blood [81].Flanagan et al. Nutrition & Metabolism 2010, 7:30
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Glutaryl-CoA dehydrogenase (GCDH) deficiency is an
inborn error of lysine and tryptophan metabolism that
results in increased formation and excretion of glutaric
acid (GA), 3-hydroxyglutaric acid (3-OH-GA), glutaconic
acid and glutarylcarnitine [82]. Secondary carnitine
depletion due to increased formation and urinary excre-
tion of glutarylcarnitine is suggested to play an important
role in the neuropathogenesis of GCDH deficiency,
inducing excitotoxic neuronal damage and mitochondrial
dysfunction [83]. GCDH can be controlled nutritionally
and supplementation includes L-carnitine to avoid sec-
ondary carnitine depletion [84-87].
Hyperthyroid patients exhibit higher urinary carnitine
concentrations compared with controls while hypothy-
roid patients exhibit concomitantly lower levels [88].
However ameliorating thyroid therapies normalizes car-
nitine levels [1].
Patients with type 2 diabetes (particularly those who
are insulin dependent or have disease-related complica-
tions) seem to be at increased risk for carnitine deficiency
[5]. Diabetic polyneuropathy (DPN) is the most common
late complication of diabetes mellitus. Experimental rat
models of DPN have identified early metabolic abnormal-
ities affecting nerve conduction velocities and endoneur-
ial blood flow [89]. These abnormalities can lead to
perturbed lipid peroxidation and expression of neu-
rotrophic factors which ultimately cause degenerative
nerve function. As the structural changes progress, they
become increasingly less amendable to metabolic inter-
ventions. In both experimental models and human dia-
betic subjects, there is an initial metabolic phase that is
responsive to metabolic corrections [90,91]. As the dis-
ease progresses however it becomes increasingly non-
responsive to therapeutic interventions [92,93].
Acetyl-L-carnitine (ALC) acts on a number of levels in
the treatment of type 1 DPN. Clinical trials of ALC have
shown ameliorating effects on nerve conduction slowing,
neuropathic pain, axonal degenerative changes and nerve
fiber regeneration [89].
Trauma, sepsis and wound healing
The metabolic process in trauma and sepsis includes
greatly accelerated proteolysis and resulting protein loss
in skeletal muscle [94]. It is known that sepsis patients
have depleted carnitine stores at the cellular level [95]. In
the liver, the rate of synthesis of selected proteins (i.e.,
albumin, transferrin, prealbumin, retinol-binding pro-
tein, and fibronectin) is decreased, whereas acute phase
protein synthesis is accelerated [94]. Tissues character-
ized by fast replicating cells also show reduced protein
synthesis. Carnitine has been trialed in cases of sepsis
and found to retard protein loss without affecting protein
metabolism in target tissues [94].
The pathophysiology of bacterial-endotoxin mediated
tissue damage may involve the interplay of reduced host
carnitine levels and pathogenic requirement of carnitine
for growth and survival in the host [95]. The endogenous
carnitine pool could be a major determinant of mounting
an effective immune and inflammatory response towards
invading pathogens [95]. This altered carnitine metabo-
lism has been implicated in the multiple organ failure in
subjects with systemic inflammatory response syndrome
and toxic shock. Carnitine levels are reduced in patients
suffering Gram-negative sepsis and urinary loss of carni-
tine is proportional to the degree of injury [96]. Prophy-
lactic use of carnitine in such situations has been shown
to reduce the endothelial damage caused by lipopolysac-
charide (LPS) and TNF-α. It has been further suggested
that carnitine deficiency might negatively impact cardiac
function which might in turn, further contribute to the
outcome of patients suffering sepsis [97-99]. There has
even been suggestion that maintenance of normal carni-
tine levels might inhibit muscle wasting, hepatic lipogen-
esis, hypertriglycerdemia and decreased fatty acid
oxidation that are seen in sepsis [95].
A proportion of infants and children with sepsis prog-
ress to cardiac failure as part of multiple system organ
failure (hepatic, renal, cardiac, pulmonary) [100]. Eaton et
al. [100] have suggested that inhibition of myocardial
CPT I activity may be a common feature of systemic
inflammation, or of inflammation localized to the heart.
A study of plasma and urinary levels of free carnitine
and short-chain acyl-carnitines in surgical patients
showed that the septic state was associated with
increased urinary excretion of free carnitine and lower
plasma levels of short-chain acyl-carnitines [101]. The
authors suggested that theoretically, carnitine supple-
mentation during total parenteral nutrition might be of
benefit in sepsis.
Literature regarding wound healing and carnitine is
sparse. In relation to burns and wound healing; one study
involving 14 patients with severe burns over eight days
showed dramatically increased levels of excreted carni-
tine [102]. There was a positive relationship between
extent of burn and carnitine output [1]. Decreased wound
healing exhibited by dialysis patients is most likely a con-
sequence of the malnutrition suffered by these patients.
McCarty and Rubin suggest supplementation of micro-
nutrients including carnitine to aid wound healing in dia-
betics [103].
It has been shown that carnitine has a significant dose-
dependent effect in promoting random pattern skin flap
survival [104]. However Koybasi and Taner found that
although there was a tendency toward faster healing, in a
group of experimental rats receiving the drug L-carnitine,
there was no significant promotion of secondary wound
healing [105].Flanagan et al. Nutrition & Metabolism 2010, 7:30
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Malnutrition, fasting and vegetarianism
Reduced plasma carnitine levels have been noted in mal-
nourished children [106] and adults [107]. Levels gener-
ally improve with dietary intervention [1]. Kwashiorkor
and marasmus represent clinical forms of protein-energy
malnutrition (PEM) [108]. Carnitine levels in children
suffering PEM are low but reach normal levels following
protein repletion [108]. Malnourished children have low
levels of many enzymes and it is likely that cofactors for
carnitine could be lacking as well. There is a positive cor-
relation between albumin and plasma carnitine levels in
PEM and plasma albumin is a widely used indicator of
PEM [108]. A negative correlation between free carnitine
and both triglycerides and cholesterol indicates that L-
carnitine may be utilized under conditions of augmented
lipolysis. There have been varying reports of urinary free-
carnitine excretion with PEM as either increasing [108]
or decreasing [109]. Finally, incremental growth was seen
in 22 of 33 carnitine-administered patients who pre-
sented with failure to thrive [110] and this was attributed
to the role of carnitine as a muscle growth factor.
Experiments with fasted and calorie-restricted rats
showed increased mRNA concentrations of acyl-CoA
and CPT-1 in the liver, heart and kidneys compared to
control animals due to upregulation of PPARα [111].
These studies demonstrated that fasting upregulates the
plasma membrane OCTN2 carnitine transporter in the
liver, heart, kidneys and in rats with strong caloric restric-
tion, additionally in skeletal muscle [111]. Fasting or
caloric restriction was shown to increase the ratio of free
carnitine to acetylcarnitine in most tissues analyzed. The
authors suggest that the amount of Acetyl-CoA in the
mitochondrion available for esterification of free carni-
tine was reduced in fasted or energy-restricted animals
leading to increased tissue carnitine concentrations while
acetylcarnitine levels were reduced [111]. These meta-
bolic adaptations during fasting, that are triggered by
PPARα, serve to minimize the use of protein and carbo-
hydrates as fuel to allow survival during long periods of
energy deprivation.
Oxidized fat was shown to upregulate PPARα and
OCNT2 and lead to reduced rate of weight gain com-
pared to controls, indicating an impairment of the feed
conversion ratio [112]. Since there is increased OCTN2
expression in the small intestine in response to oxidized
fat, and OCTN2 binds not only carnitine but various
drugs, it is suggested by the authors that OCTN2 might
be harnessed to improve absorption of various drugs
[112].
A study by Karlic and colleagues found that a vegetar-
ian diet has a significant impact on genes regulating
essential features of carnitine metabolism [113]. Elevated
plasma membrane OCTN2 carnitine transporter expres-
sion was observed in vegetarians compensating for lower
carnitine levels obtained from the diet. Thus a vegetarian
lifestyle has an impact on fat metabolism causing a
remarkable stimulation of carnitine uptake [113].
Neuroprotection and dementia
In the brain, the role of carnitine in isotonicity is crucial
since alteration of tonicity would affect nerve excitability
due to ion fluctuation. Further, brain cells are unable to
swell due to the rigidity of the skull [19].
Hepatic encephalopathy (HE) is a significant cause of
morbidity and mortality in advanced cirrhotic patients
[58]. Although the mechanisms by which carnitine pro-
vides neurological protection are unknown, a systematic
review of the literature confirmed that L-acyl-carnitine is
promising as a safe and effective treatment for HE [58].
One suggested mechanism of carnitine action is its
reduction of serum ammonia levels leading to improved
psychometric measures [63-65]. Acetyl-L-carnitine is
neuroprotective when administered at supraphysiological
concentration [114]. There is much interest in its clinical
application in various neural disorders such as
Alzheimer's disease and painful neuropathies [114].
Neuronal ceroid lipofuscinoses (NCLs) are a group of
autosomal-recessive hereditary lysosomal storage dis-
eases caused by mutations in at least 8 genes (CLN1-
CLN8) [115]. These disorders are characterized by mas-
sive accumulation of autofluorescent lysosomal storage
bodies in most cells of the CNS and associated severe
degeneration of the CNS [115]. There appears to be an
anomalous storage of mitochondrial ATP synthase sub-
unit c that is neither the result of mutation nor enhanced
expression of the protein but rather a slower degradation
of the mitochondrial ATP synthase in comparison with
normal cells [116]. Acetyl-L- carnitine has been shown to
be therapeutic in treatment of this disease [114]. Traina
and colleagues suggest that ALC might rebalance the dis-
orders underlying neuronal ceroid lipofuscinosis disease
which are related to a disturbance in pH homeostasis.
This lack of homeostasis affects acidification of vesicles
transported to the lysosomal compartment for degrada-
tion [114].
Several investigators have studied the effect of acetyl-L-
carnitine administration on older individuals with
dementia [117]. Although the statistical evaluation of sev-
eral of these "studies" were inadequate with some reports
presenting only "clinical impressions," all investigators
noted some improvement in cognitive function and posi-
tive effects of neuropsychological parameters in elderly
patients with dementia subsequent to the administration
of acetyl-L-carnitine [117].
An increasing number of studies have demonstrated
the efficacy of secondary antioxidants, such as acetylcar-
nitine, to reduce or to block neuronal death that occurs in
the pathophysiology of Alzheimer's disease. These studiesFlanagan et al. Nutrition & Metabolism 2010, 7:30
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have suggested that there may be mechanisms beyond
antioxidant activities playing a neuroprotective role
[118]. Based on the evidence that heat-shock proteins
(Hsps) can exert neuroprotective effects against oxidative
stress-related injury and that nutritional antioxidants are
a b l e  t o  u p r e g u l a t e  H s p s  i n  n e u r o n s,  u s e  o f  n u t r i t i o n a l
antioxidants such as carnitine/acetyl-L-carnitine has
been advocated to counteract the oxidative stress-
induced brain damage in Alzheimer's disease [67,119].
Similarly, carnitine/acetyl-L-carnitine has been used in
treatment of degenerative neuronal function in older
D o w n ' s  S y n d r o m e  p a t i e n t s  s i n c e  u p o n  a u t o p s y  i t  w a s
revealed that almost 100% of these patients over 40 years
of age had symptoms of dementia [117]. However acetyl-
L-carnitine was not found to benefit young men suffering
Down's Syndrome [117].
Heart disorders and supplementation in cardiovascular 
disease
Human skeletal and cardiac muscles contain relatively
high concentrations of carnitine received from the
plasma, since they are incapable of carnitine biosynthesis
[1]. The heart is one of the organs most affected in carni-
tine-acylcarnitine carrier (CAC) deficiency [120]. By cat-
alyzing the carnitine/acylcarnitine exchange, CAC allows
the import of fatty acyl moieties into the mitochondria
where they are oxidized by the β-oxidation pathway. This
pathway is the major source of energy for the heart [120].
Cardiomyopathy, cardiac arrhythmia, (likely due to the
accumulation of long-chain fatty acids and acylcarnitines
that cannot be oxidized), cardiac insufficiency and respi-
ratory distress arise from CAC deficiency [120]. Carni-
tine deficiency has been associated with heart failure [5].
The mechanism(s) underlying the effects of L-carnitine
(LC) in cardiovascular diseases are not well clarified.
Miguel-Carrasco et al. [121] demonstrated in a rat model
that chronic administration of LC reduces blood pressure
and attenuates the inflammatory process associated with
arterial hypertension.
In opposition to the reported beneficial effects of carni-
tine overload, Diaz et al. [122] demonstrated that carni-
tine worsened the recovery of contractile function in
transient ischemia. In addition, carnitine supplementa-
tion increased contracture of the heart shortly after rep-
erfusion. Diaz and colleagues concluded that in
conditions where it does not increase glucose oxidation,
carnitine supplementation worsens both injury and
recovery of contractile function after transient ischemia
in perfused rat heart [122].
L-carnitine has been shown to have favorable effects in
patients with severe cardiovascular disorders, such as
coronary heart disease, chronic heart failure and periph-
eral vascular disease [123-125]. In patients with chronic
heart disease, administration of L-carnitine over 12
months led to attenuation of left ventricular dilatation
and prevented ventricular remodeling while reducing
incidence of chronic heart failure and death [125]. In
ischemia, L-carnitine reduces myocardial injury mainly
through improving carbohydrate metabolism and by
reducing the toxicity of high free fatty acid levels [124].
The protective effect of L-carnitine on ST-elevation myo-
cardial infarction has been documented. Following an
acute myocardial infarction prompt L-carnitine adminis-
tration and subsequent maintenance therapy attenuates
progressive left ventricular dilatation [126]. L-carnitine
reduces early mortality but not overall risk of death or
heart failure at 6 months [127]. L-carnitine supplementa-
tion also prevents ventricular enlargement and dysfunc-
tion, reduces the infarct size and cardiac biomarkers, and
diminishes the total number of cardiac events including
cardiac deaths and nonfatal infarction [128,129]. Xue and
colleagues suggest that the beneficial effects of L-carni-
tine in cardiovascular disease are due to the resumption
of normal oxidative metabolism and restoration of myo-
cardial energy reserves [128,129].
Carnitine has been widely recommended as a supple-
m e n t  i n  c a r d i o v a s c u l a r  d i s e a s e .  H o w e v e r ,  i t  s h o u l d  b e
noted as mentioned previously, in conditions where it
does not increase glucose oxidation, carnitine supple-
mentation worsens both injury and recovery of contrac-
tile function after transient ischemia in the perfused rat
heart [122].
Neuromuscular disease
Myopathy can be seen with biochemically defined defects
in mitochondrial substrate transport or utilization,
including the myopathic form of carnitine deficiency;
CPT II deficiency (which most often presents with exer-
cise intolerance and myoglobinuria and is discussed
below) [130]. Patients with Duchenne dystrophy and
Becker dystrophy showed lower carnitine levels in muscle
biopsies than controls [131] though these levels were
higher than in patients suffering primary carnitine defi-
ciency as a result of severe muscle damage [1].
CPT II Type 1 "muscle" phenotype, which is the most
frequent clinical presentation, is characterized by recur-
rent episodes of muscle pain, rhabdomyolysis (a poten-
tially fatal disease that occurs suddenly and with great
force destroying skeletal muscle) and myoglobinuria.
This deficiency is often triggered by heavy exercise, and
can also manifest as a result of exposure to cold, infec-
tion, emotional distress, and/or fasting [132].
Drug interactions
Cyclosporin A induced nephrotoxicity has been dis-
cussed above. Valproic acid (VPA) is a broad-spectrum
anti-epileptic drug [133]. It is usually well tolerated, but
rare serious complications such as VPA-induced hepato-Flanagan et al. Nutrition & Metabolism 2010, 7:30
http://www.nutritionandmetabolism.com/content/7/1/30
Page 9 of 14
toxicity (VHT) and VPA-induced hyperammonaemic
encephalopathy (VHE) may occur in some patients who
receive VPA chronically [133]. It has been suggested that
VHT and VHE may be promoted by carnitine deficiency,
either pre-existing or deficiency induced by VPA [134].
VPA is used to treat psychiatric disorders and as such
there is an association with accidental or deliberate over-
dose, the incidence of which is increasing [135,136]. Ben-
efits of oral L-carnitine in relation to VPA-associated
deficiency and related adverse effects have been reported
[137-139]. Carnitine supplementation during VPA ther-
apy in high-risk patients is now recommended by some,
especially by pediatricians [133]. L-carnitine therapy
c o u l d  a l s o  b e  v a l u a b l e  i n  t h o s e  p a t i e n t s  w h o  d e v e l o p
VPA-induced hepatotoxicity or VPA-induced hyperam-
monaemic encephalopathy [133].
Al-Majed and colleagues [140] found that carnitine
deficiency and oxidative stress are risk factors during
development of cisplatin (CDDP)-induced cardiomyopa-
thy and that carnitine supplementation, using propionyl-
l-carnitine, prevents the progression of CDDP-induced
cardiotoxicity.
Aging and bone loss
Adverse effects of aging are, in part, attributed to
decreases in mitochondrial function and increases mito-
chondrial oxidant production [141]. L-carnitine levels in
tissues have been found to decline with age [142]. Acetyl-
L-carnitine (ALCA) fed to aged rats was shown to reverse
age-related declines in tissue L-carnitine levels and also
reversed a number of age-related changes in liver mito-
chondrial function; however, high doses of ALCA
increased liver mitochondrial oxidant production [143].
Liu et al. demonstrated that memory loss in old rats is
associated with brain mitochondrial decay and RNA/
DNA oxidation. Partial reversal was obtained by feeding
acetyl-L-carnitine and/or R-alpha -lipoic acid [144].
ALCA, together with alpha-lipoic acid, was shown to
improve mitochondrial energy metabolism and decrease
oxidative stress leading to improved memory in aged rats
[144,145]. Several studies have reported that supplement-
ing rats with both L-carnitine and alpha-lipoic acid halts
age-related increases in reactive oxygen species (ROS),
lipid peroxidation, protein carbonylation, and DNA
strand breaks in heart, skeletal muscle and brain, con-
comitant with improvement in mitochondrial enzyme
and respiratory chain activities [146-149]. In a clinical
trial of Levocarnitine-treated elderly patients [150], there
was significant improvement in total fat mass, total mus-
cle mass, total cholesterol, LDL-C, HDL-C, triglycerides,
apoA1, and apoB with concomitant decreases in physical
and mental fatigue. These data suggest that administra-
tion of levocarnitine to healthy elderly subjects may result
in reduction of total fat mass, and increase of total muscle
mass, may be reduce fatigue and serum lipids.
Ca rn i t i n e  l ev e l s  d ecr eas e  wi t h  a g e  [ 1 5 1] .  P a t a n o  a n d
colleagues suggest that this decrease in energy availability
might compromise osteoblast activity and bone remodel-
ing in an age-related manner [152]. It has been shown
that cells of the osteoblastic lineage generate 40-80% of
their energy demands through fatty acid oxidation [153].
Patano et al. [152] suggest that modulation of fatty acid
oxidation may regulate the amount of energy available for
protein synthesis in osteoblasts. Using an aging ovariec-
tomized rat model they found supplementation of L-car-
nitine can influence bone density and slow the rate of
bone turnover by slowing bone loss and improving bone
microstructural properties through decreasing bone
turnover [154]. The study reported that benefits of carni-
tine are comparable with other drugs of choice in terms
of effectiveness in preventing BMD loss due to aging.
Colluci and colleagues [150] used an in vitro model to
suggest that carnitine supplementation in the elderly may
stimulate osteoblast activity and decrease age-related
bone loss.
Dry eye and retinal disorders
Dry eye is a common disease of the ocular surface that is
associated with corneal surface irregularity and blurred
vision [155-158]. In artificial tear formulations, L-carni-
tine is considered a "compatible solute". Use of carnitine
in artificial tears has demonstrated rapid and consistent
improvements in signs and symptoms in patients with
dry eye [159] suggesting an intrinsic homeostatic role for
carnitine in the eye [160]. Recently, Pescosolido and col-
leagues [161] evaluated the presence of carnitine in tears
of dry eye patients and suggested that the damage
incurred on the ocular surface of dry eye patients may, in
part, be due to a lack of carnitine in the tear film of these
patients relative to the ocular surface cells and suggested
use of solutions containing carnitine to reduce this dam-
age. Increased tear osmolarity in dry eye disease has been
found to stimulate production of inflammatory cytokines
and matrix metalloproteinases by ocular surface epithe-
lial cells [155]. Tears of patients with dry eye show signifi-
cantly increased osmolarity, with a mean value of 343
mOsm compared with 302 mOsm in healthy controls
[162]. Corrales and colleagues [155] showed that osmo-
protectants such as L-carnitine reduce activation of
(mitogen-activated protein) MAP kinases, the phospho-
rylation of which leads to an increased expression of
cytokines, chemokines and matrix metalloproteases
[155]. These factors mediate and control immune and
inflammatory responses. Dysregulation of these factors
in the eye can lead to corneal melting and scarring with
deleterious consequences. Under hyperosmolar condi-
tions, L-carnitine was found to protect against stress acti-Flanagan et al. Nutrition & Metabolism 2010, 7:30
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vation of corneal epithelial cells by reducing levels of
kinase [155]. This activity of carnitine can by likened to
the use of sunscreen reducing downstream effects of UV
(pain, redness, edema, exfoliation, melanin production,
collagen damage) by physically limiting the cellular dam-
age/stress from UV, not by the pharmacological targeting
of cytokines, receptors, etc. that otherwise bring about
the painful sunburn. Peluso et al. [19] further suggest that
decreased levels of carnitine in the eye in experimental
diabetes (as reported by Pessotto et al. [163]) might be
related to osmotic stress rather than pathological modifi-
cation of the eye lens and that chronic aberration of
osmotic pressure causes net loss of carnitine which can
lead to triggering of cataracts.
Mitochondrial trifunctional protein (MTP) defects are
disorders of mitochondrial fatty acid β-oxidation pathway
of which progressive pigment chorioretinopathy is a
long-term complication [164]. Chorioretinopathy
emerges during early childhood as granular pigmentation
of the central fundus with or without pigment clumping
which may progress to chorioretinal atrophy, high myo-
pia, posterior staphyloma and low vision [165]. Current
treatment includes a low fat, high carbohydrate diet and
avoidance of fasting which dramatically improves prog-
nosis allowing long term survival. However the dietary
impact is controversial [166]. Roomets et al. examined
the expression of CPT-1 isoforms in photoreceptor cells
and retinal pigment epithelial cells that are known to be
affected morphologically and functionally in complete
MTP deficiency and deficiency of long-chain 3-hydroxya-
cyl-CoA hydratase (LCHAD) [167]. They concluded that
the mitochondrial fatty acid β-oxidation pathway proba-
bly plays an active metabolic role in retinal pigment epi-
thelium and other neuroretinal cell types. They further
suggest that accumulation of 3-hydroxylated intermedi-
ates of long-chain fatty acids may contribute to the patho-
genesis of retinopathy in MTP deficiencies [164].
Conclusion
Carnitine as a nutritional supplement has, since the
1960s, been promoted as beneficial in a number of disor-
ders of human carnitine deficiency of impaired fatty acid
oxidation, suggesting that nutritional or pharmacologic
supplements of carnitine might be beneficial in some dis-
orders [168]. However it should be noted that according
to Stanley [168], over the past 40 years, there have been
only two clear examples of disorders directly due carni-
tine deficiency that have provided evidence of unequivo-
cal benefit from carnitine treatment.
Most healthy people, including vegetarians, produce
and gain sufficient carnitine from their diets. Carnitine is
thus considered a "conditionally essential" nutrient since
individuals' requirements might exceed dietary intake
during specific disease states. The increase of L-carnitine
in plasma via oral administration, even up to and exceed-
ing 2 mg, is limited, since L-carnitine has a very poor
absorption and bioavailability, a very high renal clearance,
and active uptake into tissues. Intravenous administra-
tion of L-carnitine might prove more effective, however
where kidney function is not impaired, as more than 95%
of L-carnitine filtered by glomeruli is retained and excess
exogenous L-carnitine is readily excreted once the active
transporters are saturated.
Despite this, in a number of disease states much work
has been done regarding the effects of prophylactic levels
of carnitine though some controversy and misconcep-
tions relating to its use in general nutrition need to be
addressed. Carnitine is a natural compound, free from
toxicity when given in oral doses up to several grams and
thus supplements are often recommended in primary and
secondary deficiencies. Since carnitine is readily
excreted, supplemental ingestion is well tolerated. Evi-
dence from both rodent and human studies supports
health-related benefits when used as a therapeutic agent.
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